Sale!

Duloxetine 100 Mg · Strip

Filagra Dxt 100 Mg+30 Mg Tablets

Rx (Prescription Medicine)

Original price was: USD $ 117.56.Current price is: USD $ 94.05.

You save USD $ 23.51 (20%)

USD $ 9.41 per tablet

Upload prescription Ask about this medicine
  • Dispatched from licensed pharmacy partners
  • Tracked worldwide shipping
  • Secure payment

Key facts

Active ingredient
Duloxetine
Strength
100 Mg, 30 mg
Form
Tablet
Drug class
Generic
Brand
Filagra Dxt
Manufacturer
Fortune Healthcare
Pack sizes
10 Tablets

Description

What Is Filagra DXT 100+30 mg?

Filagra DXT 100+30 mg is a combination tablet containing sildenafil citrate 100 mg and duloxetine hydrochloride 30 mg, designed for the management of men with both erectile dysfunction (ED) and premature ejaculation (PE) — two sexual dysfunctions that frequently co-exist and are often mutually reinforcing. Sildenafil (100 mg) is a selective phosphodiesterase type 5 (PDE5) inhibitor that enhances the penile erection response to sexual stimulation; duloxetine (30 mg) is a serotonin–norepinephrine reuptake inhibitor (SNRI) with established efficacy in delaying ejaculation by modulating central and spinal serotonergic ejaculatory control pathways. By combining both mechanisms in a single tablet, Filagra DXT addresses the dual burden of ED and PE without requiring separate prescriptions or complex multi-drug regimens.

The prevalence of co-existing ED and PE is clinically significant. Studies show that 30–50% of men with PE have concomitant ED, and conversely, men with ED frequently develop secondary PE due to anxiety about erection, heightened arousal from ED-related performance pressure, and the tendency to rush intercourse before erection is lost. Treatment of either condition in isolation often leaves the patient inadequately treated — treating ED alone may not resolve PE, and treating PE alone will not restore erectile function. The combination of sildenafil 100 mg + duloxetine 30 mg addresses both simultaneously, improving sexual confidence, intercourse duration, erectile quality, and partner satisfaction.

Mechanism of Action

Sildenafil 100 mg — PDE5 Inhibition

Sildenafil is a selective, reversible inhibitor of phosphodiesterase type 5 (PDE5), the principal enzyme that degrades cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle. During sexual stimulation, nitric oxide (NO) released by NANC nerve endings activates guanylyl cyclase, generating cGMP which relaxes corpus cavernosum smooth muscle, reduces arterial resistance, and allows erection. By inhibiting PDE5-mediated cGMP degradation, sildenafil prolongs and amplifies the erectile response to sexual stimulation. The 100 mg dose provides maximum PDE5 inhibition within the licensed dose range — appropriate for men with more severe or refractory ED, or for those who have previously had inadequate response to lower sildenafil doses.

Duloxetine 30 mg — SNRI and Ejaculatory Delay

Duloxetine inhibits the presynaptic reuptake of both serotonin (5-HT) and norepinephrine (NE) at central and spinal synapses, increasing their intrasynaptic concentration. The ejaculatory reflex is controlled by a spinal ejaculatory generator — a network of interneurons in the lumbar spinal cord — that is under tonic serotonergic inhibitory control via descending 5-HT pathways from the nucleus paragigantocellularis (nPGi) in the brainstem. Increasing synaptic 5-HT concentration via SNRI activity enhances this inhibitory tone on spinal ejaculatory neurons, raising the ejaculatory threshold and delaying ejaculation. The 30 mg dose in Filagra DXT is a lower dose than the standard antidepressant dose (60–120 mg) and is calibrated to provide ejaculatory delay while minimising dose-dependent adverse effects (nausea, insomnia, hypertension) seen at higher SNRI doses.

Pharmacokinetic Interaction Between the Two Components

Sildenafil is predominantly metabolised by CYP3A4 and CYP2C9; duloxetine is predominantly metabolised by CYP1A2 and CYP2D6. There is no significant pharmacokinetic interaction between sildenafil and duloxetine through shared metabolic pathways. However, duloxetine inhibits CYP2D6 to a moderate degree, and patients who are CYP2D6 poor metabolisers may have higher duloxetine exposure. The combination is designed for on-demand use rather than daily administration — consistent with sildenafil’s on-demand PDE5 inhibitor profile and with the established on-demand use paradigm for duloxetine in PE (unlike SSRIs, which are more effective for PE with daily use).

Indications

Concurrent Erectile Dysfunction and Premature Ejaculation

Filagra DXT 100+30 mg is indicated for adult men with concomitant erectile dysfunction and premature ejaculation where both conditions require treatment simultaneously. It is appropriate for men who have previously used sildenafil alone for ED with suboptimal satisfaction due to co-existing PE, men with primary PE in whom ED has developed, and men newly presenting with both dysfunctions simultaneously. The combination formulation improves treatment adherence by reducing pill burden compared to two separate medications and synchronises the onset of action of both components.

Dosage and Administration

Standard dose: One tablet (sildenafil 100 mg + duloxetine 30 mg) taken approximately 1–2 hours before anticipated sexual activity.

Timing: Take 1–2 hours before activity. Sildenafil onset is approximately 30–60 minutes; duloxetine’s ejaculatory delay effect reaches peak intensity within 1–2 hours of dosing.

Frequency: On-demand use; maximum one tablet per 24-hour period.

Food: High-fat meals significantly delay sildenafil absorption — take at least 2 hours after a high-fat meal for optimal sildenafil onset. Duloxetine absorption is less affected by food.

Renal impairment: Use with caution in moderate renal impairment. Avoid in severe renal impairment due to both sildenafil and duloxetine accumulation.

Hepatic impairment: Avoid in moderate to severe hepatic impairment — both sildenafil and duloxetine undergo extensive hepatic metabolism, and exposure increases substantially in hepatic impairment.

Contraindications

  • Organic nitrates (absolute): GTN, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite — severe hypotension risk from sildenafil component.
  • MAO inhibitors (absolute): Concomitant use with monoamine oxidase inhibitors (MAOIs — phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) is absolutely contraindicated due to serotonin syndrome risk from duloxetine component. Allow ≥14 days after stopping an MAOI before starting duloxetine-containing products.
  • Known hypersensitivity to sildenafil, duloxetine, or any excipient.
  • Severe cardiovascular disease where sexual activity is inadvisable.
  • Severe hepatic or renal impairment.
  • Uncontrolled narrow-angle glaucoma (duloxetine increases intraocular pressure).
  • Concomitant use with riociguat.

Warnings and Precautions

Serotonin syndrome: The duloxetine component carries a risk of serotonin syndrome — particularly when combined with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, St John’s Wort, lithium). Serotonin syndrome presents with mental status changes, autonomic instability, and neuromuscular abnormalities. Avoid combination with serotonergic drugs unless clinically necessary, and monitor for symptoms.

Cardiovascular risk of sildenafil component: Assess cardiovascular fitness for sexual activity before prescribing. The nitrate contraindication is absolute — ensure the patient is not on any form of nitrate (including recreational amyl nitrite). The hypotensive effect of sildenafil is enhanced by alpha-blockers, antihypertensive agents, and alcohol.

Suicidality (duloxetine): Although the duloxetine dose in Filagra DXT is lower than standard antidepressant doses, duloxetine carries a class warning for increased suicidal ideation in young adults during the initial weeks of SNRI use. Monitor for mood changes, particularly in patients with underlying depressive disorder.

Urinary hesitancy: Duloxetine’s norepinephrine activity increases urethral smooth muscle tone and may cause urinary hesitancy or retention — monitor in patients with lower urinary tract symptoms or benign prostatic hyperplasia.

Priapism: As with all PDE5 inhibitors, prolonged erection (>4 hours) requires immediate medical attention.

Adverse Effects

Adverse effects reflect both the sildenafil and duloxetine components:

  • Sildenafil-related: Headache, flushing, nasal congestion, dyspepsia, visual disturbances (chromatopsia), dizziness.
  • Duloxetine-related: Nausea (particularly on first use — take with food), dry mouth, insomnia, fatigue, hyperhidrosis (sweating), constipation.
  • Combined/additive: Dizziness (enhanced by combined hypotensive and CNS effects), tachycardia.

Drug Interactions

  • Nitrates: Absolute contraindication — severe hypotension (sildenafil).
  • MAO inhibitors: Absolute contraindication — serotonin syndrome (duloxetine).
  • CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, erythromycin): Significantly increase sildenafil exposure — reduce dose or avoid combination.
  • CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): Increase duloxetine exposure substantially — avoid combination or use with caution.
  • CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): Increase duloxetine exposure — monitor for duloxetine adverse effects.
  • Other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, St John’s Wort): Increased serotonin syndrome risk.
  • Alpha-blockers and antihypertensives: Additive hypotension (sildenafil component).

Storage

Store below 25°C in a cool, dry place away from direct sunlight. Keep in the original blister packaging. Keep out of reach of children. Do not use after the expiry date printed on the packaging.

Related Products

For the higher duloxetine dose combination (sildenafil 100 mg + duloxetine 60 mg), see Filagra DXT Plus 100+60 mg. For sildenafil 50 mg without PE treatment, see Zenegra 50 mg Tablets. For tadalafil + dapoxetine combination, see Super Tadalis SX (Tadalafil 20 mg + Dapoxetine 60 mg).

References

  • National Library of Medicine MedlinePlus. Sildenafil. Available at: https://medlineplus.gov/druginfo/meds/a699015.html
  • National Library of Medicine MedlinePlus. Duloxetine. Available at: https://medlineplus.gov/druginfo/meds/a604030.html
  • Mayo Clinic. Duloxetine (Oral Route). Available at: https://www.mayoclinic.org
  • Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. PubMed PMID: 29746562
  • Althof SE, McMahon CG, Waldinger MD, et al. An Update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. Sex Med. 2014;2(2):60–90. PubMed PMID: 25356297

Additional information

Brand Name

Molecule

,

Strength

100 Mg, 30 mg

Medicine Form

Tablet

Packaging Type

Strip

Pack Quantity

10 Tablets

Country Of Origin

India

Medicine Type

Generic

Rx Status

Rx (Prescription Medicine)

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Same molecule & strength

No other brand of this exact strength is stocked, so these are other strengths of Duloxetine, Sildenafil Citrate. Never switch dose without asking your prescriber.

On this page
  1. Key facts
  2. Description
  3. Additional information
  4. Reviews (0)
  5. Same molecule

Content integrity

Medically reviewed by

Renu Meena, B.Pharm (RSPC Reg. No. 55661)

Registered Pharmacist

Renu Meena is a registered pharmacist (Rajasthan State Pharmacy Council, Reg. No. 55661) with a Bachelor of Pharmacy (B.Pharm) from Rajasthan University of Health Sciences (RUHS), Jaipur. She reviews IndogenMed medicine pages for dosing, safety and interaction accuracy against official prescribing information. With 4+ years of experience across clinical pharmacy and medical content, her work is shaped by pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11 and safety reporting requirements.

Last reviewed 16/11/2026

Shipping to your country

Options
Shipping
Free over
USD $ 20,550.00